Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model
Advances in Nanoparticles · 2026 · 15 (04) · 81-112
DOI: 10.4236/anp.2026.154004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Nanoparticles, 2026. Verfasst von Zahra Fakhroueian und 3 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Fakhroueian, Z., Eghtedardoost, M., Massiha, A., & Abbasvandi, F. (2026). Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model. Advances in Nanoparticles, 15(04), 81-112. https://doi.org/10.4236/anp.2026.154004
Vancouver
Fakhroueian Z, Eghtedardoost M, Massiha A, Abbasvandi F. Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model. Advances in Nanoparticles. 2026;15(04):81-112. doi:10.4236/anp.2026.154004
BibTeX
@article{Fakhroueian2026,
author = {Fakhroueian, Zahra and Eghtedardoost, Marzieh and Massiha, Alireza and Abbasvandi, Fereshteh},
title = {Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model},
journal = {Advances in Nanoparticles},
year = {2026},
volume = {15},
number = {04},
pages = {81--112},
doi = {10.4236/anp.2026.154004}
}
EUVIMED